Zoetis Inc. (ZTS) Receives Average Recommendation of “Buy” from Analysts
Zoetis Inc. (NYSE:ZTS) has been given an average rating of “Buy” by the fourteen ratings firms that are covering the company. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $55.83.
A number of analysts have commented on the stock. Zacks Investment Research raised shares of Zoetis from a “hold” rating to a “buy” rating and set a $55.00 price objective for the company in a research note on Wednesday, November 16th. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $53.00 target price on shares of Zoetis in a report on Thursday, November 3rd. Jefferies Group reiterated a “buy” rating and issued a $63.00 target price on shares of Zoetis in a report on Sunday, October 16th. Stifel Nicolaus reiterated a “buy” rating and issued a $58.00 target price on shares of Zoetis in a report on Wednesday, October 12th. Finally, Bank of America Corp. assumed coverage on Zoetis in a report on Thursday, September 29th. They issued a “buy” rating and a $60.00 target price on the stock.
Zoetis (NYSE:ZTS) opened at 49.89 on Wednesday. Zoetis has a 12 month low of $38.26 and a 12 month high of $53.14. The firm has a market capitalization of $24.64 billion, a PE ratio of 35.97 and a beta of 1.05. The firm’s 50-day moving average is $50.68 and its 200-day moving average is $49.45.
Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Wednesday, November 2nd. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.06. Zoetis had a net margin of 14.10% and a return on equity of 72.96%. The company earned $1.20 billion during the quarter, compared to analyst estimates of $1.22 billion. During the same period in the prior year, the firm earned $0.50 earnings per share. The business’s quarterly revenue was up 2.2% on a year-over-year basis. On average, equities research analysts expect that Zoetis will post $1.94 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 1st. Shareholders of record on Thursday, November 3rd will be issued a dividend of $0.095 per share. The ex-dividend date is Tuesday, November 1st. This represents a $0.38 annualized dividend and a yield of 0.76%. Zoetis’s dividend payout ratio (DPR) is presently 27.54%.
In other news, insider Roxanne Lagano sold 9,797 shares of the stock in a transaction that occurred on Tuesday, November 8th. The stock was sold at an average price of $50.43, for a total value of $494,062.71. Following the completion of the sale, the insider now directly owns 8,063 shares of the company’s stock, valued at $406,617.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Heidi C. Chen sold 32,097 shares of the stock in a transaction that occurred on Thursday, September 1st. The shares were sold at an average price of $50.98, for a total value of $1,636,305.06. Following the completion of the sale, the insider now directly owns 46,060 shares of the company’s stock, valued at $2,348,138.80. The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.
Several large investors have recently bought and sold shares of the stock. Piedmont Investment Advisors LLC acquired a new stake in Zoetis during the third quarter valued at $17,114,000. Price T Rowe Associates Inc. MD boosted its position in shares of Zoetis by 12.3% in the third quarter. Price T Rowe Associates Inc. MD now owns 34,863,382 shares of the company’s stock valued at $1,813,244,000 after buying an additional 3,806,515 shares during the period. Quantitative Systematic Strategies LLC boosted its position in shares of Zoetis by 38.7% in the third quarter. Quantitative Systematic Strategies LLC now owns 21,536 shares of the company’s stock valued at $1,101,000 after buying an additional 6,012 shares during the period. LPL Financial LLC boosted its position in shares of Zoetis by 74.5% in the third quarter. LPL Financial LLC now owns 72,856 shares of the company’s stock valued at $3,811,000 after buying an additional 31,099 shares during the period. Finally, Ameritas Investment Partners Inc. boosted its position in shares of Zoetis by 31.1% in the third quarter. Ameritas Investment Partners Inc. now owns 11,835 shares of the company’s stock valued at $616,000 after buying an additional 2,810 shares during the period. 93.89% of the stock is owned by institutional investors.
Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a diversified business, marketing products across over eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock), and dogs, cats and horses (collectively, companion animals), and within over five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.
Receive News & Stock Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related stocks with our FREE daily email newsletter.